The treatment difference between the two groups was first seen very early in the trial

The treatment difference between the two groups was first seen very early in the trial. European Medicines Agency issued guidance that trials should be conducted to prove that antihyperglycemic agents have acceptable CV risk profiles. In this article, the authors review the study designs and results of CV outcomes trials conducted with sodiumCglucose cotransporter 2